High-throughput sequencing of related individuals has become an important tool for studying human disease. However, owing to technical complexity and lack of available tools, most pedigree-based sequencing studies rely on an ad hoc combination of suboptimal analyses. Here we present pedigree-VAAST (pVAAST), a disease-gene identification tool designed for high-throughput sequence data in pedigrees. pVAAST uses a sequence-based model to perform variant and gene-based linkage analysis. Linkage information is then combined with functional prediction and rare variant case-control association information in a unified statistical framework. pVAAST outperformed linkage and rare-variant association tests in simulations and identified disease-causing genes from whole-genome sequence data in three human pedigrees with dominant, recessive and de novo inheritance patterns. The approach is robust to incomplete penetrance and locus heterogeneity and is applicable to a wide variety of genetic traits. pVAAST maintains high power across studies of monogenic, high-penetrance phenotypes in a single pedigree to highly polygenic, common phenotypes involving hundreds of pedigrees.
A r t i c l e s
Linkage analysis evaluates recombination events between genetic markers and potential causal alleles in families to map phenotypic loci 1 . In comparison, genetic association tests detect genetic markers that are correlated with phenotypes among unrelated individuals. Traditionally, both types of analyses use genetic markers such as microsatellites or single nucleotide polymorphisms (SNPs). Thus, the corresponding statistical methods usually test against the null hypothesis that the focal variants are in linkage or linkage disequilibrium with causal variants and do not assume that causal variants are directly observable. High-throughput sequencing techniques now allow comprehensive detection of rare and private variants throughout the exome or whole genome. To take advantage of the increased availability of sequencing data, rare-variant association tests (RVATs) have been developed to aggregate rare variants in each gene, which reduces multiple comparison problems and increases the statistical power for discovering disease-associated genes [2] [3] [4] . Once disease loci have been identified through association or linkage studies, variant classifiers such as SIFT 5 and PolyPhen-2 (ref. 6 ) are often used to prioritize rare mutations that are likely to be damaging.
Association tests and linkage analysis use two different types of information to perform disease locus mapping. Both methods take advantage of genetic recombination information; however, association signals derive mostly from the historical recombination events in the population, whereas linkage analysis makes use only of recombination events that occurred in the pedigree under investigation. In a biological sense, these two types of data are related; yet, from a statistical point of view, they provide orthogonal and thus complementary information about the disease locus. Currently, comprehensive analysis of pedigree sequencing data is a labor-intensive process that requires an array of bioinformatics tools (linkage analysis, association tests and variant classifiers). Given these challenges, most pedigree sequencing studies apply a simplified and suboptimal approach involving a series of ad hoc filtering criteria 7 . A few existing tests use family data in rarevariant association tests (for example, refs. 8 and 9). By accounting for pedigree relationships using an appropriate covariance matrix, these tests use information from related pedigree members without inflating type I error with large sample sizes. However, these methods capture only association signals and do not incorporate linkage or variant-classification information.
One particular challenge in pedigree analysis lies in mapping de novo causal mutations, i.e., private mutations that occurred in the germline of affected individuals. De novo mutations can cause rare Mendelian diseases 10 as well as common complex diseases such as autism 11 . However, the analyses of de novo mutations face a few nontrivial challenges: (i) De novo mutations are not in linkage with any other genetic markers; as a result, traditional linkage methods cannot analyze them; (ii) sequencing technologies will generate a number of erroneous variant calls that resemble de novo mutations, and failing to properly account for the platform-specific genotyping errors may introduce either type I or type II errors; (iii) in large-scale pedigree studies of complex genetic diseases, both de novo and inherited mutations can contribute to the disease prevalence; separately analyzing the risk of these two types of disease mutations will result in a loss of power.
Previously, we developed the Variant Annotation, Analysis and Search Tool (VAAST) 12, 13 . VAAST implements an RVAT that uses a composite likelihood ratio test (CLRT v ) to incorporate two types of genetic information: allele frequency differences between cases and controls and variant classification information from phylogenetic conservation and predicted biochemical function. VAAST performs variant classification in conjunction with the association test. Variants with a high likelihood under the disease model (for example, variants with large differences in case and control frequencies and producing nonconservative amino acid changes) receive high CLRT scores, whereas variants predicted as neutral by VAAST receive a score of 0. For this reason, VAAST is robust to inclusion of common variants. More recently, we demonstrated that VAAST is applicable to a wide array of disease scenarios using both simulations and empirical data sets 13 .
Here we present pVAAST, a tool that combines linkage analysis, casecontrol association and functional variant prediction in a unified statistical framework that offers much higher power relative to each of the individual methods. We demonstrate the utility of pVAAST in a variety of simulated and real data sets involving dominant, recessive and de novo patterns of inheritance across a broad range of family-based study designs.
RESULTS
pVAAST pVAAST searches through the personal genomic data from disease pedigrees, sporadic cases and unaffected controls to identify genes associated with disease. To do so, it combines logarithm of odds (lod) scores with association signals to generate a unified test statistic that offers a higher power compared to either method alone. Unlike lod scores in traditional parametric linkage analysis, the lod score in pVAAST is designed for sequence data. Specifically, the statistical model assumes that the dysfunctional variants influencing disease-susceptibility can be directly detected. As a result, the pVAAST lod score is in general more powerful than traditional linkage analysis with sequencing data, as we show below. Moreover, this assumption allows us to calculate lod scores for de novo mutations, which is not possible with traditional linkage analysis, given that de novo mutations are not in linkage with other markers. pVAAST is built upon the CLRT used in VAAST, but in addition integrates the linkage information (quantified by a lod score) as a separate log likelihood ratio in the pVAAST CLRT (CLRT p ) (Fig. 1) . pVAAST evaluates the significance of the CLRT p score using a combination of a randomization test and a genedrop simulation 14 (Online Methods).
Simulated family data
We first evaluated the performance of pVAAST to identify variants causing rare Mendelian diseases using simulated family data and unaffected control genomes (we recorded the parameterization of all pVAAST experiments in this manuscript in Supplementary Note 1). We investigated three disease models using both association-and pedigree-based approaches: dominant, recessive and dominant resulting from de novo mutations. In all models, we compared pVAAST with two rare-variant association tests, VAAST 12 and SKAT-O 3 (version 0.91; using the 'linear.weighted' kernel and 'optimal.adj' method). For comparison, we also included a nonparametric linkage method based on an idealized scenario with perfect knowledge of identity-by-descent (IBD) states in all families and a two-point parametric linkage analysis using Superlink 15 for dominant and recessive models (Supplementary Note 2). For the de novo model, we included a Poisson-based test, which detects excess inheritance error in cases (Supplementary Note 2) . pVAAST correctly controls for type I error in all three scenarios (Supplementary Fig. 1 ).
We used each method to analyze the required sample size at four different levels of population-attributable risk (PAR) 16 (Fig. 2a-c) .
Under all disease models, pVAAST was consistently the most powerful approach. The required sample size of pVAAST was usually an order of magnitude lower than for nonparametric linkage analysis, demonstrating the value of case-control sequencing data in the identification of genes associated with rare Mendelian diseases. Under dominant and de novo models, pVAAST typically required half the sample size of VAAST, and one-fifth the sample size of SKAT-O. Under the de novo model, the Poisson-based test was more powerful than rare-variant association tests alone (VAAST and SKAT-O), but substantially less powerful than pVAAST. In general, parametric linkage analysis performed worse than nonparametric (Fig. 2a-b and Supplementary Table 1), which is expected given that our nonparametric test was based on perfect knowledge of IBD states.
We also benchmarked the performance of pVAAST in common, complex diseases by simulating four-generation families (Fig. 2d) . We compared the relative performance of four different choices of sequenced pedigree members: affected parent-offspring pairs, affected first-cousin pairs, affected second-cousin pairs and the entire pedigree. We simulated mildly deleterious risk alleles with a selection coefficient of 0.001, which resulted in an average MAF of 1.9 × 10 −3 (Fig. 2e) . With all pedigree members shown in Figure 2e , pVAAST required only 66% of the sample size of VAAST, and with affected first-or second-cousin pairs, pVAAST required 79% the sample size of VAAST (Fig. 2e) . We observed no performance improvement with affected parent-offspring pairs in pVAAST compared to VAAST. With a selection coefficient of 0.01 (average MAF = 2.2 × 10 −4 ) (Fig. 2f) , we observed a similar trend but with slightly better pVAAST performance in all scenarios. pVAAST correctly controlled for type I error in all scenarios (Supplementary Fig. 2 ). For both the rare and common disease simulations, we also compared the performance of pVAAST to ASKAT 9 (version 1.2d, build 2013-09-05), an extension of SKAT npg that accommodates family-based studies. However, ASKAT controls for familial relationships through asymptotic assumptions, and for the relatively small sample sizes that we evaluated, the type I error of ASKAT was inflated ( Supplementary Fig. 3a-f ).
De novo inheritance in an enteropathy pedigree We performed whole-genome sequencing on a family quartet and used pVAAST to identify the potential causal mutation for a child with undiagnosed enteropathy (Fig. 3a) . The proband was a 12-year-old male with severe diarrhea, total villous atrophy and hypothyroidism. Both parents and the sibling of the proband were unaffected. The phenotype was most consistent with the IPEX syndrome (OMIM 304790), but clinical sequencing of the FOXP3 and IL2RA genes revealed no pathogenic mutations. We analyzed this pedigree using both the dominant and recessive models in pVAAST. Under the dominant model, the highest-ranking gene, STAT1, had a P value of 3.97 × 10 −6 . The only variant in this gene is a de novo mutation in the affected child, with a lod score of 0.70 and a CLRT p score of 11.724. The second ranking gene was PAX3 (P = 3.33 × 10 −3 ; lod score = 0 and CLRT p score = 11.047). STAT1 was the only gene in the genome with a lod score >0.1; genes with lod scores between 0.1 and 0 fit an inheritance pattern of dominance with incomplete penetrance. Under the recessive model, no gene has a P value <1.18 × 10 −3 (Fig. 3b) . We validated the de novo inheritance pattern by genotyping the offspring and parental genotypes with Sanger sequencing. Other than this mutation, we did not identify any exonic variation in STAT1 in the family. This heterozygous mutation is observed only in the proband but not in the parents or unaffected sibling.
The de novo mutation found in the affected child is a single-nucleotide guanine-to-adenine mutation, causing the amino acid change T385M in the DNA-binding motif of STAT1; the reference allele-encoded threonine is conserved among almost all sequenced vertebrate genomes 17 . STAT1 encodes a transcription factor belonging to the signal transducers and activator of transcription family; both gain-and loss-of-function mutations in STAT1 cause human disease 18 . Gain-of-function mutations in STAT1 cause autosomal dominant chronic mucocutaneous candidiasis (CMC) [19] [20] [21] and an IPEX-like phenotype 22 . The T385M mutation was reported as a cause of CMC in a Japanese patient 23 and a Ukrainian patient 24 . These data support T385M as the causative mutation for this patient's phenotype, and demonstrate pVAAST's ability to identify a causal de novo mutation from a family quartet with a single affected proband.
Dominant inheritance in a cardiac septal defect pedigree
We analyzed whole-genome sequencing data from a previous study 25 on a single pedigree affected with cardiac septal defects and having an autosomal dominant pattern of inheritance (Fig. 4a) . Previously 25 , the G296S mutation in GATA-binding protein 4 (encoded by GATA4) was identified as the cause of cardiac septal defects in this pedigree using genome-wide linkage mapping followed by sequencing of the GATA4 coding region and functional studies. pVAAST successfully identified GATA4 with genome-wide significance (P = 2.0 × 10 −9 ; Fig. 4b ). The mutation encoding G296S had a CLRT p score of 38.4 At PAR = 0.1 in a, the required sample size to achieve 80% by the parametric linkage test is greater than the maximal sample size that we evaluated (1,000); thus we did not show this data point. (d-f) Benchmark experiments on simulated common complex disease pedigrees. (d) Simulated pedigree structure. Individuals labeled 'A' were always affected; other individuals were allowed to be either affected or unaffected in the rejection sampling. (e) Required sample size to achieve 80% power when selection coefficient is 0.001. (f) Required sample size to achieve 80% power when selection coefficient is 0.01. In e and f, PAR was 0.05. Sample size is defined as the number of pedigrees used for the analysis. Type I error was set to 5 × 10 −4 . In all experiments 1,000 control genomes were used. npg A r t i c l e s (CLRT v score = 13.2; lod score = 5.47), and no other variants received a positive CLRT v or lod score in GATA4. The second-ranking gene was ITIH2, with a P value of 2.3 × 10 −5 and a lod score of 1.51. Because the prevalence parameter (disease prevalence in general population) was set to 0.01 to match that of cardiac septal defects, no other gene received a positive lod score in the pedigree. ASKAT was not applicable to this example owing to the small sample size ( Supplementary  Fig. 3g ). When VAAST analyzed the genomic sequence of a single affected individual in the cardiac septal defect pedigree (the affected individual in the second generation), GATA4 was ranked forty-first genome-wide, with a P value of 2.0 × 10 −3 ( Supplementary Fig. 4) .
We also analyzed the cardiac septal defect pedigree using a two-point parametric linkage test implemented in Superlink 15 . The mutation encoding G296S in GATA4 has a lod score of 5.13 and was the highest-scoring variant genome-wide. Assuming 2ln(10 lod ) is χ 2 distributed with two degrees of freedom (penetrance and recombination frequency), the P value of the mutation encoding G296S from two-point linkage analysis was 7.32 × 10 −6 .
Recessive inheritance in a Miller's syndrome pedigree
We investigated the performance of pVAAST on a recessive disease, Miller's syndrome, using previously generated 7 whole-genome sequencing data from a two-generation pedigree (Fig. 5a) . The two offspring are affected with Miller's syndrome and primary ciliary dyskinesia, both of which are rare recessive Mendelian diseases. The two diseases are caused by compound heterozygous mutations in the DHODH and DNAH5 genes, respectively 7 . All four individuals in the family quartet were sequenced. pVAAST identified only five genes with positive lod scores, and the two disease-causal genes (DHODH and DNAH5) were ranked first and second genome-wide (Fig. 5b) , with P values of 3.3 × 10 −5 and 1.3 × 10 −4 , and CLRT v scores of 27.9 and 30.8, respectively. The lod scores were 1.204 in both cases. In both genes, only the two causal mutations received positive scores; all other variants had scores of 0.
We also explored the performance of pVAAST after removing one affected child (B01) from the pedigree. That is, we converted the original Miller's syndrome pedigree to a trio family with two unaffected parents and one affected child. In this scenario, DHODH and DNAH5 were ranked first and thirteenth genome-wide, respectively ( Supplementary Fig. 5a ), both with lod scores of 0.602. We also ran VAAST over the genome-sequencing data of only one affected child (i.e., not using the data from the parents and the affected sibling). DHODH and DNAH5 were ranked tenth and twenty-seventh, respectively (Supplementary Fig. 5b ). In our previous work, by enforcing a strict filtering method based on inheritance patterns and minor allele frequencies, VAAST was also able to identify the correct causal genes in this pedigree but was unable to produce an accurate P value that accounted for the familial relationships 12 .
Challenging situations in pedigree studies
In linkage analysis, factors such as incomplete penetrance, locus heterogeneity and missing phenotypes negatively affect linkage signals and thus reduce disease-gene identification power. The cardiac septal defect pedigree data presented above (Fig. 4) is a large pedigree with no locus heterogeneity and very high penetrance (93.3%) for the mutation encoding G296S. We modified the genotype and phenotype data from this pedigree (Supplementary Note 3) to benchmark pVAAST in four scenarios: (i) missing phenotypes, (ii) reduced penetrance, (iii) locus heterogeneity and (iv) reduced number of informative meioses in the family. For each test case, we evaluated the lod score and the genome-wide ranking of GATA4 (ranked by P values). The lod score reported by pVAAST was approximately a monotonic function of each of the four parameters and was highly correlated with the classic twopoint parametric lod score (Fig. 6) . pVAAST was robust to pedigrees with missing phenotype data. For example, when 82% of pedigree members had unknown phenotypes, the lod score of GATA4 was 1.5 and genome-wide ranking was first (Fig. 6a,b) . Reduced penetrance generally decreased the lod score without significantly compromising npg the genome-wide ranking (Fig. 6c,d) . Specifically, the genome-wide ranking of GATA4 was consistently first until the penetrance dropped below 40%; even with penetrance of 20%, GATA4 was ranked eighth genome-wide. In comparison, locus heterogeneity had a greater impact on power (Fig. 6e,f) . When locus heterogeneity was modest, GATA4 always ranked first or second. However, when the proportion of affected individuals carrying G296S fell to 50%, the lod score dropped below 0.2, and the genome-wide ranking was beyond fiftieth. The original family has 20 informative meiosis events, and our results show pVAAST ranked GATA4 first genome-wide even when there are only 11 informative meioses in the family (Fig. 6g) . Furthermore, with only six meioses, pVAAST still ranked GATA4 second genome-wide. This suggests that for a rare Mendelian disease with high penetrance and low locus heterogeneity within the family, the risk gene can often be identified among the top hits genome-wide using a typical three-generation pedigree.
For comparison, we evaluated the genome-wide ranking of GATA4 with three alternative approaches. In the first approach, we calculated a two-point parametric lod score at each polymorphism site with Superlink 15 and designated the lod score from the best-scoring site overlapping a protein-encoding gene as the gene lod score. We then ranked all genes by the gene lod scores. We also attempted to perform multipoint linkage analysis with Merlin 26 , but this proved computationally infeasible. In the second approach, we applied the same procedure to the pVAAST lod score to calculate the ranking (Fig. 6) . Finally, we evaluated a hard-filtering approach that only considered variants that perfectly fit the expected inheritance pattern with minor allele frequencies below 0.5% (Supplementary Note 3) .
We found that the pVAAST lod score was consistently more robust than the classic two-point parametric lod score in challenging scenarios such as low penetrance, high locus heterogeneity, small sample size and large fraction of unknown phenotypes. The ranking of GATA4 with pVAAST lod scores was usually one order of magnitude higher than with Superlink. This performance difference is perhaps not surprising given that traditional linkage analysis tests the hypothesis of disease linkage rather than disease causation and was developed for sparse marker data rather than complete sequence data. Ranking using pVAAST P values instead of lod scores further improved the accuracy of disease-gene identification, and the improvement was pronounced when the penetrance was low or the phenotypes were missing for a large fraction of the pedigree. Hard-filtering makes strict assumptions about the expected inheritance pattern and minor allele frequency of the causal mutation. When these assumptions hold, hard-filtering has comparable performance to traditional two-point linkage analysis but is less robust compared to pVAAST and pVAAST lod scores. However, hard filtering performed very poorly when any of these assumptions were violated (Fig. 6e) . Figure 6 The genome-wide ranking and lod score of GATA4 in challenging situations of pedigree studies. (a-h) lod scores and genome-wide rankings corresponding to differing levels of unknown phenotypes (a,b), degrees of penetrance (c,d), proportion of affected individuals being G296S mutation carriers (e,f) and number of informative meioses (g,h). For genome-wide rankings, y axis is shown in log scale, and four methods were compared (pVAAST, Superlink, pVAAST lod and a hard-filtering approach).
A r t i c l e s
We also investigated the impact of incomplete penetrance, locus heterogeneity and unknown phenotypes in conjunction with smaller family sizes. To do so, we used only a subset of the individuals in the original cardiac septal defect pedigree to reduce the number of informative meiosis. We evaluated the genome-wide ranking of GATA4 using pVAAST, pVAAST lod scores, two-point linkage analysis in Superlink, multipoint linkage analysis in Merlin 26 and hard filtering (Supplementary Figs. 6-8) . The ranking of GATA4 was highest when using pVAAST in almost all scenarios, which is consistent with the results involving the entire family (Fig. 6) .
DISCUSSION
Because pVAAST employs the same CLRT framework as its predecessor, VAAST, a comparison of these two algorithms demonstrates the power gained by using inheritance information from pedigrees. In dominant rare Mendelian diseases, the improvement is remarkable: when an additional affected cousin was sequenced, pVAAST required only half the number of families as VAAST (Fig. 2a) , regardless of the level of locus heterogeneity. These results demonstrate that although linkage analysis is usually substantially less powerful than a rare-variant association test (RVAT) alone, in these scenarios, linkage provides orthogonal information for disease-gene identification, and this information can greatly improve the power of association tests. Although RVATs were initially developed for common genetic disorders, we previously demonstrated that they are more powerful than standard hard-filtering approaches often used to analyze rare Mendelian diseases 12, 13 . The current study extends this work and provides a unified test that computes a single P value over the combined linkage and association evidence.
Classic linkage methods were designed for sparse genetic-marker data and model the recombination frequencies between genetic markers and disease to identify large genomic regions in the family that may harbor a causal mutation. In contrast, pVAAST is designed for sequence-based studies and assumes that the causal mutations can be directly assayed. Our model also incorporates an additional unobserved risk locus (latent locus) to capture an additional layer of genetic architecture of the disease, enabling pVAAST to accurately model complex diseases in families with phenocopies or locus heterogeneity. For these reasons, the pVAAST lod score typically outperformed both the classic two-point (Fig. 6) and multipoint (Supplementary Figs. 6-8 ) parametric lod scores in the scenarios we evaluated, particularly in challenging scenarios relevant to common, complex disease involving reduced penetrance, locus heterogeneity, small sample size or missing phenotypes.
Our results from the enteropathy, cardiac septal defect and Miller's syndrome pedigrees demonstrate that pVAAST can successfully identify rare, Mendelian disease-causing variants from genome-wide searches involving only a single pedigree. In particular, the identification of STAT1 as the likely cause of enteropathy in a small pedigree establishes that excellent statistical resolution can be achieved in a small family with a disease-causing de novo mutation (Fig. 3) . It should be noted, however, that in de novo disease models the genotyping error rate has a large impact on power (Supplementary Fig. 9) , and with higher genotyping error rates that can result from earlier sequencing or variant-calling technologies, a potential de novo mutation is more likely to be a sequencing error and less likely to be a true de novo event. The results shown in Figures 3-5 also show that pVAAST is robust to technical complications that are present in real genomic data but not represented in simulations, such as genotyping errors, missing genotype calls and differences in sequencing platforms between cases and publicly available controls.
An important practical consideration is which family members to sequence to achieve optimal power. For rare Mendelian diseases with high penetrance, the choice is straightforward given that the inheritance path of the causal mutation can be inferred. However, for common genetic disorders, determining the optimal choice of family members is more complex. Sequencing more distantly related individuals increases the number of informative meioses in the pedigree but also increases the probability of phenocopies. Here we show that in a common complex disease with a modest level of locus heterogeneity (PAR = 0.05 and only 40% of affected individuals carrying mutations with odds ratio >1.1 in the gene of interest; see also Supplementary Note 2), sequencing affected first-or second-cousin pairs yields substantially better results than sequencing affected parent-offspring pairs in the same family (Fig. 2e-f) . Sequencing the entire extended family offers a modest improvement over cousin pairs, consistent with previous findings 27 .
If sample size is not a limiting factor, another consideration is the cost effectiveness of sequencing pedigrees versus unrelated cases. For example, as shown in the simulations of dominant inheritance, pVAAST requires half the number of pedigrees as VAAST but requires two individuals per pedigree to be sequenced (Fig. 2a) . Thus, with affected cousin pairs, the two approaches are equally cost effective. However, in rare Mendelian diseases with high penetrance, because the P value decreases exponentially with the number of informative meiosis (Supplementary Fig. 10 ), sequencing affected pairs more distant than the first cousin is more cost-effective than sequencing only unrelated index cases from each pedigree. A two-stage design can also be cost effective. Specifically, in the first stage, only unrelated cases are sequenced, and VAAST prioritizes genes according to their significance levels. In the second stage, candidate risk variant in the relatives of affected carriers are genotyped, and pVAAST analyzes the original sequence data with the additional genotype information. This approach can be economical given the relative costs genotyping and whole-exome sequencing. Although pVAAST is primarily designed for sequence data, it is also applicable to exome chip genotyping data. pVAAST was recently used to identify candidate genes associated with an increased risk of suicide from exome chip data in extended high-risk pedigrees 28 .
Because pVAAST combines linkage analysis and case-control association, all the caveats from these methods are applicable. In particular, loci not causally related to disease may be in linkage disequilibrium with a causal locus in association studies. Therefore, as with traditional linkage analysis and association tests, rejection of the null hypothesis in pVAAST can establish disease-gene association but cannot rule out the possibility that the association results from a linked locus that is causal. As with other case-control association tests, uncontrolled confounding covariates can potentially inflate type I error rates in pVAAST. To control for covariates, pVAAST can interface with the BiasedUrn package 29 (http://cran.r-project. org/web/packages/BiasedUrn/index.html) to conduct a covariate adjusted randomization test (Supplementary Note 4) .
Existing family-based sequence-analysis approaches are typically applicable to only a narrow range of studies. Hard filtering approaches that enforce strict inheritance patterns are appropriate for studies involving small families with rare Mendelian diseases but do not provide robust statistical interpretations and do not scale to large families or common, complex diseases 7, 30 . Sequence analysis in large families typically involve multistep ad hoc procedures in which linkage analysis or IBD mapping is used to identify large genomic regions followed by the application of a series of hard filters based on inheritance patterns, variant annotations and population allele frequencies 31 . In addition, approaches that rely primarily on hard filters do not scale well to multifamily studies 12, 13 . ASKAT is a family-based rare-variant association test that is designed for large, multifamily studies but is not presently applicable to studies involving relatively small sample sizes. Methods used to identify diseasecausing de novo mutations can efficiently combine statistical evidence from multiple families but require parent-offspring trios and cannot incorporate evidence from families with inherited disease 32 . npg pVAAST is also applicable to non-disease trait mapping in nonhuman species. In typical genetic screens in model organisms, researchers crossbreed individuals with different phenotypes for generations and then map the locations of possible causal variants using linkage analysis. When sequencing data are available, pVAAST could be an attractive alternative to traditional mutation mapping in these studies, as it incorporates additional information from association signals and functional predictions of the mutations. This is especially true for species with high levels of genetic diversity such as rice 33 and maize 34 , where a large proportion of near-neutral variants may complicate the identification of mutations responsible for the phenotype. The integrated variant classification functionality in VAAST and pVAAST may mitigate these challenges 35, 36 .
In contrast to existing methods, pVAAST performs well across a wide range of study designs, from a single small family with a rare, Mendelian disease to hundreds of families with common, complex genetic diseases and arbitrary pedigree structures. pVAAST is a flexible, general-purpose tool for identifying disease-associated genes that combines variant classification, rare-variant association testing and linkage analysis in a unified statistical framework to increase the power and reduce the technical complexity of family-based sequencing studies.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The human genome sequencing data for the enteropathy and cardiac septal defects pedigrees have been submitted to the database of Genotypes and Phenotypes (dbGaP), and accession codes will be provided as soon as they are available. Meanwhile, inquires about the data should be directed to M.Y. or C.D.H. 
ONLINE METHODS
Basic lod score calculation in pVAAST. In classic two-point parametric linkage analysis, the marker under investigation is usually assumed not to be causal but rather linked with the actual causal variant with a certain recombination probability (r). Under the null hypothesis, r = 0.5, which indicates that the marker and causal mutation are unlinked. Under the alternative hypothesis, r is a free parameter. Given the disease prevalence, allele frequency of the marker and causal allele and the penetrance of the causal allele, the likelihood of alternative and null model can be calculated for given values of r using the Elston-Stewart algorithm 37 . The log 10 ratio of the maximum likelihood of the alternative and null model is the lod score.
For simplicity, we use the term causal to refer to any variant that directly increases disease risk, regardless of penetrance. Our model assumes that the disease is caused by either the locus under investigation (current locus) or some other unlinked locus in the genome (latent locus). In both models, the current and latent loci are unlinked, and there is no epistatic interaction between the alleles. The null model states that variant(s) in the latent locus cause the disease with some probability, and the current locus is not causal. The alternative model states that variants in both the current and latent loci can independently cause the disease, with different probabilities. In other words, the null model attributes the disease phenotype solely to the latent locus, and the alternative model allows variants in both the current and latent loci to be independently causal. We then maximize the likelihoods of the alternative and null models over ρ c (genotype disease probability vector for the current variant), ρ l (genotype disease probability vector for the latent locus) and f l (minor allele frequency of the latent locus) and calculate the log10 likelihood ratio as the lod score. Formally, Given ρ c , ρ l , f c and f l , all of the aforementioned probabilities can be calculated with the Elston-Stewart algorithm 15 in linear computational time relative to the family size. We estimate f c from the allele frequency in a control population and perform a grid search over ρ c , ρ l and f l in the specified order to maximize the likelihood. By default, we explore ρ c and ρ l values ranging from 0 to 1 with increment of 0.1, and in addition the following values: 0.001, 0.01 and 0.999. We explored the following f l values: 5 × 10 −7 , 5 × 10 −4 , 5 × 10 −3 , 0.01, 0.02, 0.05, 0.5 and 0.999. The resolution of the grids is tunable. In all our experiments, the aforementioned parameters offer a good balance between algorithm efficiency and statistical power, although using a finer grid may increase the power of pVAAST at the cost of longer computation time. For the dominant model, a heterozygous genotype is sufficient to be considered as a risk genotype; for a simple recessive model, a homozygous genotype is required, with the exception of sex chromosomes. Compound heterozygous scenarios are discussed below.
If more than one family is present, for each variant, we maximize the likelihood under the assumptions that ρ c is consistent across families but ρ l and f l varies between families using a nested grid search. Then, within each family, the lod of one variant is chosen to be the gene lod score of this family. By default, the variant with the highest CLRT v score is chosen, but the user can opt to use CLRT p score or lod score alone as well. In practice, we found that in large pedigrees, using the CLRT p score as a selection criterion may yield more favorable results. Finally, we sum the gene lod score from multiple families to generate the overall pVAAST lod score.
Extending the dominant model to de novo mutations. We accommodate de novo mutations in our model by allowing Mendelian inheritance errors to occur in the pedigree likelihood calculation. Specifically, in the Elston-Stewart algorithm 37 , if the offspring carries a mutation absent from both parents, then this transmission has a probability of m (mutation rate per site per generation in human genome; default 1. 2 × 10 -8 (ref. 7) ). Accordingly, we also randomly introduce Mendelian inheritance error in our gene-drop simulations 14 with probability equal to the genotyping error rate.
Extending the recessive model to compound heterozygotes. Compound heterozygotes require special attention because the genotype vectors (g l and g c ) now involve more than one variant site. Under the recessive model we are specifically interested in the situation where two deleterious mutations occur at two different chromosomes of the same gene, so that both copies are defective. To illustrate, consider a gene with three polymorphism sites, i, j and k. A straightforward approach to calculate the gene lod score would be to calculate the lod for all pairwise combination of heterozygous variant sites within the gene (i.e., i + j; i + k; and j + k) separately and then select the highest lod score. This requires the evaluation of n(n − 1)/2 combinations, where n is the number of variant sites in the gene. However, this approach is flawed because it assumes the genotype disease probabilities for all pairs of sites are independent, which is incorrect. Instead, we assume that any variant in the gene is either causal (D-variants) or neutral (N-variants) 38 with the same relative risk. For example, if a gene has four heterozygous sites i, j, k and l, within which i, j, and k are causal, then an individual with at least two mutations at i, j and k sites on two different chromosomes would be at risk; otherwise she will not be at risk.
Under this model, we can construct a Boolean risk vector for a gene to denote whether each variant within the gene is a D-variant or N-variant. If we know the underlying risk vector for some gene, then we can easily determine the genotype of an individual by evaluating whether he or she carries at least one D-variant on each chromosome. Then the calculation of lod score is reduced to the simple recessive case described above. However, finding the optimal risk vector is not trivial, as a brute-force approach to find the risk vector maximizing the lod score has a complexity of O(2 n ), where n is the number of sites in the gene. To make this more efficient, we use an MCMC method 39 to approximate the optimal risk vector. Briefly, given a particular risk vector and the phenotype probability for each genotype, the joint likelihood for all sequenced and phenotyped individuals can be calculated as where ρ r is the probability that an individual with a risky genotype is affected; ρ n is the probability that an individual with a neutral genotype is affected; n a and n b are the total numbers of affected and unaffected individuals with a risky genotype, respectively; n c and n d are the total number of affected/unaffected individuals with neutral genotypes, respectively. Both ρ r and ρ n are configurable parameters, although we found that the performance of our MCMC method was usually insensitive to these parameters. We start with a random risk vector, and randomly select a variant site to switch to the opposite value (neutral to risky and risky to neutral). The likelihoods for both risk vectors are calculated, and we selectively accept the new risk vector according to the Metropolis-Hastings method 39 . This process is repeated until convergence or the maximal number of iterations is achieved. Lastly, we select the most likely risk vector from the Markov chain and calculate the lod score as described in the previous section.
Optionally, the joint likelihood can incorporate an empirical functional score. Let I D (k) be an indicator function for whether the kth site is a D-variant. The empirical functional score (F score) is a function of VAAST CLRT v scores across all sites in the current gene 
